



Nazionalità: Italiana | [angela.argenone@ao-rummo.it](mailto:angela.argenone@ao-rummo.it)

## ● ESPERIENZA LAVORATIVA

01/01/2018 – ATTUALE – BENEVENTO, Italia

**DIRIGENTE MEDICO I LIVELLO RADIOTERAPIA ONCOLOGICA – A.O.R.N. SAN PIO**

RESPONSABILE DELLA ELABORAZIONE DEI PIANI DI CURE DELLA PATOLOGIA MAMMARIA, DELLA NEOPLASIA DEL DISTRETTO TESTA COLLO; DELLE NEOPLASIE DEL SISTEMA NERVOSO CENTRALE E DEL MIDOLLO SPINALE, DELLE NEOPLASIE DELL'ENDOMETRIO E DEI TRATTAMENTI RADIOCHIRURGICI E STEREOTASSICI DELLA'ADDOME, PELVI E ENCEFALO, TESTA-COLLO-POLMONE  
PARTECIPAZIONE A STUDI CLINICI DELLA'ANALISI

16/10/2017 – 31/12/2017 – NAPOLI, Italia

**DIRIGENTE MEDICO RADIOTERAPIA – ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G.PASCALE**

01/09/2013 – 15/10/2013 – SIENA, Italia

**DIRIGENTE MEDICO RADIOTERAPIA – AZIENDA OSPEDALIERA UNIVERSITARIA SENESE**

ELABORAZIONE PIANI DI CURA RADIOTERAPICI E SOMMINISTRAZIONE DI CHEMIOTERAPIA IN CONCOMITANZA A RADIOTERAPIA E GESTIONE DEI PAZIENTI IN REGIME DI DH E IN REGIME DI RICOVERO ORDINARIO

01/05/2012 – 15/10/2017 – NAPOLI, Italia

**DIRIGENTE MEDICO RADIOTERAPIA – ISTITUTO PER LO STUDIO E CURA DEI TUMORI FONDAZIONE G.PASCALE**

01/05/2009 – 30/04/2013 – SIENA, Italia

**DIRIGENTE MEDICO RADIOTERAPIA – AZIENDA OSPEDALIERA UNIVERSITARIA SENESE LE SCOTTE**

01/03/2008 – 02/01/2009 – TERAMO, Italia

**DIRIGENTE MEDICO RADIOTERAPIA P.O.MAZZINI, TERAMO (ITALIA) – P.O.MAZZINI**

## ● ISTRUZIONE E FORMAZIONE

19/07/2002 – NAPOLI, Italia

**LAUREA IN MEDICINA E CHIRURGIA – Università degli studi di Napoli federico II,**

27/02/2007 – napoli, Italia

**SPECIALIZZAZIONE IN RADIOTERAPIA – Università degli studi di Napoli federico II,**

01/10/2019 – ATTUALE – NAPOLI, Italia

**INCARICO D'INSEGNAMENTO MED 36 CORSO DI LAUREA IN OSTETRICIA – UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II**

## ● **COMPETENZE LINGUISTICHE**

---

Lingua madre: **ITALIANA**

Altre lingue:

---

	<b>COMPRESIONE</b>		<b>ESPRESSIONE ORALE</b>		<b>SCRITTURA</b>
	Ascolto	Lettura	Produzione orale	Interazione orale	
<b>INGLESE</b>	B1	B1	B1	B1	B1

---

*Livelli: A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato*

## ● **COMPETENZE DIGITALI**

---

Gestione autonoma della posta e-mail | Microsoft Office | Windows | Utilizzo del browser | Google | Social Network | Posta elettronica

## ● **PROGETTI**

---

ATTUALE  
**MAMETIC**

---

**MIRASOLE**

---

## ● **PUBBLICAZIONI**

---

### **Prevention and Treatment of Radiation Induced Skin Damage in Breast Cancer**

---

Journal of Cosmetics, Dermatological Sciences and Applications, 2014, 4, 16-23  
<http://www.scirp.org/journal/jcdsa> - 2014

### **Predictability and Management of OARs Toxicity in Patients with Prostate Cancer Treated with High-Dose Radiotherapy**

---

Journal of Cancer Therapy, 2013, 4, 1452-1458  
<http://www.scirp.org/journal/jct> - 2013

### **Variability in axillary lymph node delineation for breast cancer radiotherapy in presence of guidelines on a multi-institutional platform**

---

ACTA ONCOLOGICA  
<http://dx.doi.org/10.1080/0284186X.2017.1325004> - 2017

### **A CASE OF STEVENS-JOHNSON SYNDROME POSSIBLY INDUCED BY AMIFOSTINE DURING RADIOTHERAPY**

---

Tumori, 93: 634-635, 2007  
2007

**Contouring of the Pharyngeal Superior Constrictor Muscle (PSCM). A cooperative study of the Italian Association of Radiation Oncology (AIRO) Head and Neck Group**

---

RadiotherOncol . 2014 Sep;112(3):337-42  
<https://doi.org/10.1016/j.radonc.2014.05.016> - 2014

**Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO—Head and Neck working group**

---

Head & Neck. 2019;1-9.  
<https://doi.org/10.1002/hed.25890> - 2019

**Palliative Radiotherapy Between Scientific Evidence and Technological Evolution: Role of Clinic Appropriateness an the Choice of Treatment**

---

GLOBAL JOURNAL FOR RESEARCH ANALYSIS VOLUME 3, ISSUE 10 OCT2014 ISSN No 2277-8160  
2014

**Is pain part of a systemic syndrome in head and neck cancer?**

---

SUPPORTIVE CARE IN CANCER  
<https://doi.org/10.1007/s00520-019-05147-8> - 2019

**Detection of a numeric value predictive of increased dose to left anterior descending coronary artery (LAD) in radiotherapy of breast cancer**

---

SPRINGER PLUS  
[DOI 10.1186/s40064-016-2399-7](https://doi.org/10.1186/s40064-016-2399-7) - 2016

**Inter-observer variability of clinical target volume delineation in definitive radiotherapy of neck lymph node metastases from unknown primary. A cooperative study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Group**

---

La radiologia medica  
<https://doi.org/10.1007/s11547-019-01006-y> - 2019

**Induction Docetaxel-Cisplatin Followed by Extended-field Radiotherapy in Patients with Cervical Metastases from Unknown Primary Carcinoma**

---

ANTICANCER RESEARCH 33: 1135-1140 (2013)  
2013

**Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study**

---

Oncology . 2013;84(4):251-4  
<https://doi.org/10.1159/000347232> - 2013

**Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group**

---

<https://doi.org/10.1111/odi.13755> - 2020

## **Geometric contour variation in clinical target volume of axillary lymph nodes in breast cancer radiotherapy: an AIRO multi-institutional study**

---

The british journal of radiology  
<https://doi.org/10.1259/bjr.20201177> - 2021

## **Thoracic re-irradiation with 3D-conformal or more advanced techniques: A systematic review of treatment safety by the Re-irradiation Study Group of the Italian Association of Radiation and Oncology AIRO**

---

<https://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematology>  
<https://doi.org/10.1016/j.critrevonc.2021.103500> - 2021

---

*Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".*